Coherus Oncology, Inc.
- CHRS
- NASDAQ
- Biotechnology
- Cancer Immunotherapy
- Biosimilars (Oncology)
$0.99
Today −7.48%Quote Oct 16, 2026, 08:00 PM UTC
−19.51%over the last month
Max drawdown −27.7%From 1-month high −27.7%3 months −30.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$153.0M
Quote Oct 16
Next earnings
Nov 5
Expected, not confirmed
Analyst target
$6.02
+508.1% from here
Floor
$0.98
1.3% below price
Where the price sits
17 analysts
Analyst range, low to high
$1.05$11.00
- Price $0.99
- Resistance $1.07
- Consensus $6.02
The price is just above its floor. Analysts' average target sits about 508% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CHRSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
144
Founded
2010